Payment overview · 2025
General Payments
$39.58
2 reported records · 2 companies
Healthcare provider profile · identity verified
Romulo Juan Camogliano, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · THE VILLAGES, FL · NPI 1093701310
Verified facts
What the public records show
CMS Open Payments records show Romulo Juan Camogliano, M.D. received $39.58 in general payments during 2025 across 2 reported records.
Abbott Laboratories accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.53 | 59.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.05 | 40.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.58 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 722 | 214 |
| Levothyroxine Sodium | Levothyroxine Sodium | 625 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 131 |
| Losartan Potassium | Losartan Potassium | 333 | 101 |
| Lisinopril | Lisinopril | 304 | 90 |
| Simvastatin | Simvastatin | 285 | 77 |
| Omeprazole | Omeprazole | 278 | 86 |
| Valsartan | Valsartan | 273 | 80 |
| Metformin Hcl | Metformin Hcl | 188 | 63 |
| Glipizide Er | Glipizide | 181 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 51 |
| Ezetimibe | Ezetimibe | 154 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 49 |
| Eliquis | Apixaban | 152 | 41 |
| Tramadol Hcl | Tramadol Hcl | 142 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 45 |
| Carvedilol | Carvedilol | 134 | 43 |
| Gabapentin | Gabapentin | 124 | 42 |
| Repatha Sureclick | Evolocumab | 109 | 22 |
| Furosemide | Furosemide | 99 | 33 |
| Allopurinol | Allopurinol | 96 | 30 |
| Jardiance | Empagliflozin | 94 | 26 |
| Potassium Chloride | Potassium Chloride | 94 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 43 |
| Buspirone Hcl | Buspirone Hcl | 92 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 27 |
| Alprazolam | Alprazolam | 91 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 29 |
| Finasteride | Finasteride | 86 | 24 |
| Mirtazapine | Mirtazapine | 85 | 24 |
| Sertraline Hcl | Sertraline Hcl | 85 | 27 |
| Atenolol | Atenolol | 82 | 25 |
| Synthroid | Levothyroxine Sodium | 79 | 24 |
| Azithromycin | Azithromycin | 78 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 26 |
| Clonazepam | Clonazepam | 74 | 16 |
| Celecoxib | Celecoxib | 73 | 27 |
| Trazodone Hcl | Trazodone Hcl | 71 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 19 |
| Levofloxacin | Levofloxacin | 61 | 47 |
| Montelukast Sodium | Montelukast Sodium | 61 | 20 |
| Famotidine | Famotidine | 59 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Methylprednisolone | Methylprednisolone | 53 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 51 |
| Glimepiride | Glimepiride | 50 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 17 |
| Mounjaro | Tirzepatide | 48 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 11 |
| Lorazepam | Lorazepam | 46 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 18 |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Spironolactone | Spironolactone | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 13 |
| Ozempic | Semaglutide | 39 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | 12 |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Meloxicam | Meloxicam | 34 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Lovastatin | Lovastatin | 33 | 11 |
| Baclofen | Baclofen | 32 | 20 |
| Glipizide | Glipizide | 32 | 12 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Metolazone | Metolazone | 31 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Dutasteride | Dutasteride | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.58 · 2 records | Abbott Laboratories | FREESTYLE LIBRE 3, VIVITROL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error